An Open-label, Pilot Study of RO5185426 in Previously Treated Metastatic Melanoma Patients With Brain Metastases
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Vemurafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Adverse reactions
- Sponsors Roche
- 24 Sep 2012 Results will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep/Oct 2012.
- 15 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2012 Actual patients number chnaged from 2 to 24 as reported by ClinicalTrials.gov.